Impedimed’s progress over the last year has been stellar, reflected in a share price that has risen 400% in this period. The company is successfully commercialising its ‘L-Dex’ technology, which allows early detection of lymphoedema. Canaccord believes the story has only just begun, with the substantial benefits of monitoring patients for lymphoedema after their cancer treatment getting significant recognition in the clinical community. Two key points in our updated report are that firstly, the National Comprehensive Cancer Network (NCCN) has included lymphoedema in the latest interim guidelines for both breast cancer and for cancer survivorship. These guidelines are internationally recognised as standard of care for cancer patients, and is likely to help drive widespread adoption of the product. Secondly, results from an independent clinical study published in a peer-reviewed journal demonstrated exceptional efficacy of the product. It showed that early detection of subclinical lymphoedema using L-Dex could reduce the rate of clinical grade disease in breast cancer patients to 2.8%, versus 36.4% of patients using conventional practices. We anticipate widespread adoption, and can also envisage application in other conditions. (VIEW LINK)